Dexorgen Inc.
North Bethesda, MD Doing business as Codex Biosolutions Inc. Research And Development
- UEI
- ZNUMJ4FKRC19
- CAGE
- 62JZ3
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 12358 Parklawn Dr #250a, North Bethesda, MD 20852, USA
- Website
- dexorgen.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Develop and optimize antagonists assays in ACVR1-WT, ACVR1-R206H,ACVR1-T283I and ACVR1-R206H-T283I cells | National Center for Advancing Translational Sciences | $13,200 | |
| Generation and characterization ipsc derived brain organoids from bain type x-linked mental retardation syndrome (mrxsb) | National Institute on Drug Abuse | $24,000 | |
| Htlv envelope protein production services (ambis #2225428) | National Institute of Allergy and Infectious Diseases | $25,770 | |
| Codex biosolutions:1203128 [24-000295] | National Institute on Drug Abuse | $29,400 | |
| EXPI293 stable cell line overexpressing htlv envelope protein (ambis #2183770) | National Institute of Allergy and Infectious Diseases | $22,620 |
About Dexorgen Inc.
Dexorgen Inc., operating as Codex Biosolutions Inc., is a minority-owned, small disadvantaged business specializing in advanced biotechnological research and development services. Registered in SAM.gov since 2010 and located in North Bethesda, Maryland, the company focuses on cell line development, genetic engineering, and translational science support for federal agencies. As a corporate entity, Dexorgen Inc. is classified as a for-profit organization with a specific focus on Asian-Pacific American ownership and small business certification.
The company has consistently secured federal contract awards primarily from the National Institutes of Health (NIH) agencies, including the National Center for Advancing Translational Sciences (NCATS), National Institute of Allergy and Infectious Diseases (NIAID), and the National Institute on Drug Abuse. Their contract work predominantly involves specialized scientific services such as generating stable cell lines, constructing cell lines expressing specific protein variants, and developing research tools for various scientific investigations. Recent contract awards have focused on COVID-19 research, including creating pseudoparticles for viral entry inhibition assays, constructing cell lines expressing SARS-CoV-2 spike protein variants, and developing cell lines for HTLV envelope protein production. Their contracts range in value from approximately $11,250 to $35,025, typically structured as firm fixed-price purchase orders with completion dates ranging from several months to a year. None of their identified contracts have specific set-aside designations, and they have worked on projects involving brain organoid generation, calcium channel cell line development, and genetic research supporting translational medicine.
Quick answers
What is Dexorgen Inc.'s UEI?
Dexorgen Inc.'s Unique Entity ID (UEI) in SAM.gov is ZNUMJ4FKRC19.
What is Dexorgen Inc.'s CAGE code?
Dexorgen Inc.'s CAGE code is 62JZ3.
What is Dexorgen Inc.'s primary NAICS code?
Dexorgen Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Dexorgen Inc. located?
Dexorgen Inc.'s physical address in SAM.gov is 12358 Parklawn Dr #250a, North Bethesda, MD 20852, USA.
Is Dexorgen Inc. registered in SAM.gov?
Yes. Dexorgen Inc.'s SAM.gov registration is active through March 16, 2027.
What is Dexorgen Inc.'s most recent federal award?
Dexorgen Inc.'s most recent federal contract award is Develop and optimize antagonists assays in ACVR1-WT, ACVR1-R206H,ACVR1-T283I and ACVR1-R206H-T283I cells (75N95C25P00106), from National Center for Advancing Translational Sciences, on September 18, 2025.
On GovTribe
See Dexorgen Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors